作者：
Tiago A,Mestre [1]
;
Erik,van Duijn [2]
;
Aileen M,Davis [3]
;
Anne-Catherine,Bachoud-Lévi [4]
;
Monica,Busse [5]
;
Karen E,Anderson [6]
;
Joaquim J,Ferreira [7]
;
Philipp,Mahlknecht [8]
;
Vitor,Tumas [9]
;
Cristina,Sampaio [10]
;
Chris G,Goetz [11]
;
Esther,Cubo [12]
;
Glenn T,Stebbins [11]
;
Pablo,Martinez-Martin [13]
;
Members of the MDS Committee on Rating Scales Development
作者单位：
Parkinson's Disease and Movement Disorders Center, Division of Neurology, Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Ontario, Canada. tmestre@toh.on.ca.
[1]
Psychiatry Department, Leiden University Medical Centre, and Centre for Mental Health Care Delfland, Delft, Netherlands.
[2]
Krembil Research Institute, University Health Network and Institute of Health Policy, Management and Evaluation and Rehabilitation Institute, University of Toronto, Ontario, Canada.
[3]
Assistance Publique-Hôpitaux De Paris, National Centre of Reference for Huntington's Disease, Neurology Department, Université Paris Est, Créteil; INSERM U955 E01, Institut Mondor De Recherché Biomédicale, École Normale Supérieure, Créteil-Paris, France.
[4]
School of Healthcare Sciences, Cardiff University, Cardiff, Wales, United Kingdom.
[5]
Georgetown University, School of Medicine, Washington, District of Columbia, USA.
[6]
Neurology and Clinical Pharmacology, University of Lisbon, Institute of Molecular Medicine, Lisbon, Portugal.
[7]
Department of Neurology, Innsbruck Medical University, Innsbruck, Austria.
[8]
Ribeirão Preto School of Medicine, University of São Paulo, São Paulo, Brazil.
[9]
CHDI Management/CHDI Foundation, Princeton, New Jersey, USA.
[10]
Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.
[11]
Department of Neurology, Hospital Universitário Hermanos Yagüe, Burgos, Spain.
[12]
National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain.
[13]
DOI
10.1002/mds.26675
PMID
27296904
发布时间
2018-03-16
换一批
换一批
